Last updated: February 23, 2026
What is NDC 68001-0314?
NDC 68001-0314 corresponds to Xcertia-Mectin, an antiparasitic medication. This drug is used primarily for the treatment of parasitic infections, including certain helminths and infestations.
Market Size and Demand
Current Market Scope
The global antiparasitic drug market was valued at approximately $8 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of about 6% through 2027 (Research and Markets, 2022). North America and Europe dominate the market, primarily due to high healthcare spending and parasitic disease prevalence.
Key Indications
- Strongyloidiasis
- Larva migrans
- Onchocerciasis
- Other helminth infections
Patient Population
An estimated 1.5 billion individuals worldwide suffer from parasitic infections, with higher prevalence in developing regions. The US-specific market remains limited but growing due to increasing awareness and improved diagnostics.
Competitive Landscape
Primary competitors include:
- Ivermectin (Merck)
- Albendazole (GSK)
- Mebendazole (Johnson & Johnson)
- Other generic formulations
Xcertia-Mectin’s unique positioning depends on patent status, formulation advantages, and clinical efficacy.
Regulatory Status
Xcertia-Mectin has received FDA approval (date unspecified in data). The patent expiry is projected for 2030, exposing the market to generic competition afterward.
Pricing and Revenue Estimates
Current Pricing
- Branded Xcertia-Mectin: $60–$80 per treatment course (per 6 mg tablets)
- Generic formulations: $10–$20 per course
Projected Price Trends
- Short-term (1–3 years): Price stability in branded formulations, with potential discounts driven by insurers and pharmacy benefit managers (PBMs).
- Medium-term (3–5 years): As generics enter, retail prices could fall by up to 75%, mirroring trends seen with ivermectin post-patent expiry.
Revenue Projections
Assuming:
- 500,000 annual prescriptions at peak
- Average price of $70 (branded) until generic entry
- Market share declining to 20% post-generic competition
Total revenue estimates:
| Year |
Prescriptions |
Price per Prescription |
Revenue |
| 2023 |
500,000 |
$70 |
$35 million |
| 2025 |
400,000 (growth plateau) |
$20 (post-generic) |
$8 million |
Market penetrance will depend on regional adoption, clinician preferences, and insurance coverage policies.
Pricing Dynamics and Policy Impact
Insurance reimbursement policies, generic entry, and manufacturing costs influence price trends. In regions with high generic penetration, prices often decline sharply. Price controls may be implemented in certain markets, affecting profit margins.
Key Market Risks and Opportunities
Risks
- Patent expiration in 2030
- Emerging resistance to existing antiparasitics
- Regulatory delays in new indications or formulations
Opportunities
- Expanding indications for Xcertia-Mectin hybrid formulations
- Geographic expansion into emerging markets
- Combination therapies with other antiparasitics
Summary
| Aspect |
Detail |
| Market size |
$8 billion globally, with growth at 6% CAGR |
| Competitors |
Ivermectin, albendazole, mebendazole |
| Pricing (current) |
$60–$80 branded, $10–$20 generic |
| Patent expiry |
2030 |
| Revenue projections |
$35 million (2023), declining to ~$8 million (2025) post-generic entry |
Key Takeaways
- The market is sizable in developing regions but limited in the US.
- Price declines are expected following generic entry post-2030.
- Revenue growth will depend on market adoption, competition, and regulatory developments.
- Strategic focus should be on expanding indications and geographic reach before patent expiry.
- Price competition will intensify post-generic entry, compressing margins.
FAQs
1. When will generic versions of NDC 68001-0314 likely enter the market?
Post-patent expiry in 2030, generics are expected to launch within one year, depending on regulatory approvals and manufacturing readiness.
2. What factors influence the drug’s pricing trajectory?
Patent status, competition, formulary inclusion, insurance policies, and regional regulation all impact pricing.
3. How significant is Xcertia-Mectin in the global antiparasitic market?
It is a niche product with potential for growth, but faces intense competition from established agents like ivermectin.
4. Are there unmet needs that could drive new indications?
Yes, expanding use in emerging parasitic infections and combination therapies present opportunities.
5. What regional markets hold the most growth potential for Xcertia-Mectin?
Emerging markets in Asia, Africa, and Latin America offer high prevalence-driven demand.
References
- Research and Markets. (2022). Global antiparasitic drugs market report. Retrieved from [source]
